Where does Arcutis Biotherapeutics, Inc.'s cash flow data come from?

Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$11.3M—	——	$7.41M+147%	-$15.89M+36.6%	-$25.06M-132%
Stock-based compensation	$10.69M+6.3%	$10.06M+0.2%	$10.04M-4.3%	$10.49M+7.3%	$9.78M+4.1%
Change in accounts receivable	-$1.85M-106%	$31.11M+269%	$8.43M-60.4%	$21.27M+72.3%	$12.35M-12.6%
Change in inventories	$14.58M+291,480%	$5K-99.9%	$5.89M—	$0-100%	$1.95M+636%
Change in accounts payable	$5.61M—	——	-$9.29M-1,777%	$554K+79.3%	$309K—
Change in accrued liabilities	$20.77M-11.4%	$23.45M+321%	$5.57M-73.7%	$21.23M+10,021%	-$214K-102%
Change in other assets	$11.73M+827%	$1.27M-28.1%	$1.76M+141%	-$4.3M-231%	$3.28M+4,873%
Other working capital changes	-$214K-919%	-$21K+92.6%	-$283K+3.7%	-$294K-444%	-$54K+86.6%
Amortization of intangible assets	$562K-0.2%	$563K+0.2%	$562K-0.2%	$563K-81.1%	$2.98M+852%
Net cash from operating activities	$2.24M—	——	-$1.75M—	——	-$30.38M-3,961%
Capital expenditures	$0—	——	——	$78K-87.2%	$608K—
Purchases of investments	$62.15M-30.3%	$89.18M+30.1%	$68.54M+107%	$33.15M-40.9%	$56.11M+222%
Proceeds from maturities/sales of investments	$50.82M-7.6%	$55M+27.0%	$43.3M-28.6%	$60.65M-11.4%	$68.47M+19.5%
Net cash from investing activities	-$11.33M+66.8%	-$34.18M-35.4%	-$25.25M-245%	$17.42M+48.3%	$11.75M-66.3%
Repayments of debt	——	$0—	$0—	$0—	$0-100%
Proceeds from issuance of common stock	$1.07M—	$0—	$0—	$0—	$0—
Net cash from financing activities	$1.07M-71.3%	$3.72M+152%	$1.48M+7.0%	$1.38M+249%	$395K—
Effect of exchange rate changes on cash	-$119K-302%	$59K—	——	$200K+4,900%	$4K+102%
Net increase (decrease) in cash	-$8.15M-93.3%	-$4.21M+83.6%	-$25.62M-233%	$19.33M+206%	-$18.23M+71.3%
Interest paid	$2.91M+14.4%	$2.54M-3.2%	$2.62M+1.0%	$2.6M+1.1%	$2.57M-13.1%
Accretion (Amortization) of Discounts and Premiums, Investments	$182K—	$0-100%	$551K-20.7%	$695K-19.1%	$859K-21.6%
Amortization of capitalized software and acquired intangible assets	$562K-0.2%	$563K+0.2%	$562K-0.2%	$563K-81.1%	$2.98M+852%
Operating lease liabilities	-$137K-8.7%	-$126K+16.0%	-$150K+26.5%	-$204K-2.0%	-$200K-6.4%
Increase (Decrease) in Prepaid Expense and Other Assets	$11.73M+827%	$1.27M-28.1%	$1.76M+141%	-$4.3M-231%	$3.28M+4,873%
Other Noncash Income (Expense)	-$214K-919%	-$21K+92.6%	-$283K+3.7%	-$294K-444%	-$54K+86.6%
Payment-in-kind interest	$461K0.0%	$461K+2.7%	$449K+4.2%	$431K+3.9%	$415K-84.0%
Proceeds From Sale And Maturity Of Available For Sale Securities	$50.82M—	——	——	——	$68.47M-5.2%
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs	——	$0—	$0—	$0—	$0—
Accrued payables for capital expenditures	$158K—	——	——	——	$0—
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	-$119K-302%	$59K—	——	$200K+4,900%	$4K+102%
Milestone for intangible asset not yet paid in cash	$0—	——	——	——	$10M—
Free cash flow	$2.24M—	——	-$1.75M—	——	-$30.99M-4,043%
Free cash flow	$2.24M—	——	-$1.75M—	——	-$30.99M-4,043%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Arcutis Biotherapeutics, Inc.'s cash flow data come from?: Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.